News from isis pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 18, 2015, 09:30 ET Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced...

Dec 17, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx ...

Dec 11, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) ...

Nov 10, 2015, 07:00 ET Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the advancement...

Nov 09, 2015, 07:00 ET Isis Reports Financial Results and Highlights for Third Quarter 2015

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted recent progress ...

Nov 08, 2015, 10:30 ET Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of...

Nov 06, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Nov 05, 2015, 07:00 ET Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to...

Nov 04, 2015, 07:00 ET Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Sunday, November 8 at 1:00 p.m. Eastern Time to review...

Nov 03, 2015, 06:00 ET Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive preliminary results from an ongoing investigator sponsored, open-label Phase 2...

Oct 30, 2015, 07:00 ET Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease...

Oct 27, 2015, 07:00 ET Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, November 3 at 8:00 a.m. Eastern Time to review ...

Oct 26, 2015, 07:00 ET ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the initiation of a...

Oct 23, 2015, 07:00 ET Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, November 9 at 11:30 a.m. Eastern Time to...

Oct 15, 2015, 07:33 ET Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated an open-label extension study, SHINE. The SHINE study provides...

Sep 11, 2015, 07:00 ET Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its collaboration with AstraZeneca to discover and develop antisense drugs for...

Sep 03, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Jul 29, 2015, 05:06 ET Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced...

Jul 28, 2015, 07:00 ET Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss ...

Jul 27, 2015, 07:00 ET ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with...

Jul 22, 2015, 07:17 ET Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has...

Jul 21, 2015, 07:00 ET Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with...

Jul 14, 2015, 07:00 ET Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the...

Jul 06, 2015, 07:00 ET Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), announced today that the U.S. Food and Drug...

Jun 30, 2015, 07:00 ET Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Corporate presentation at its 2015 Annual Meeting of Stockholders...